GB2469220A - A pharmaceutical composition for treating diabetes and preparation methods thereof - Google Patents
A pharmaceutical composition for treating diabetes and preparation methods thereof Download PDFInfo
- Publication number
- GB2469220A GB2469220A GB1009713A GB201009713A GB2469220A GB 2469220 A GB2469220 A GB 2469220A GB 1009713 A GB1009713 A GB 1009713A GB 201009713 A GB201009713 A GB 201009713A GB 2469220 A GB2469220 A GB 2469220A
- Authority
- GB
- United Kingdom
- Prior art keywords
- volume
- solution
- parts
- pharmaceutical composition
- taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 81
- 239000008280 blood Substances 0.000 claims abstract description 81
- 238000003908 quality control method Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 137
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 95
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 94
- 238000012360 testing method Methods 0.000 claims description 88
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 78
- 239000008103 glucose Substances 0.000 claims description 78
- 238000010438 heat treatment Methods 0.000 claims description 69
- 239000006228 supernatant Substances 0.000 claims description 48
- 239000013558 reference substance Substances 0.000 claims description 46
- 238000005406 washing Methods 0.000 claims description 42
- 239000012488 sample solution Substances 0.000 claims description 40
- 238000001816 cooling Methods 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 28
- 239000008055 phosphate buffer solution Substances 0.000 claims description 28
- 239000006187 pill Substances 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 25
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 22
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- 238000005303 weighing Methods 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 19
- 235000012907 honey Nutrition 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 239000003405 delayed action preparation Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 15
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 14
- 238000004809 thin layer chromatography Methods 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000012856 packing Methods 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- 229910002027 silica gel Inorganic materials 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 229940109239 creatinine Drugs 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 claims description 11
- 210000003734 kidney Anatomy 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 8
- 210000003497 sciatic nerve Anatomy 0.000 claims description 8
- 239000007901 soft capsule Substances 0.000 claims description 8
- UKKNXSQVJWQTAV-UHFFFAOYSA-N [Na].C(=O)N(C)C.C(C)#N Chemical compound [Na].C(=O)N(C)C.C(C)#N UKKNXSQVJWQTAV-UHFFFAOYSA-N 0.000 claims description 7
- 239000006196 drop Substances 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 229920002527 Glycogen Polymers 0.000 claims description 6
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 229940096919 glycogen Drugs 0.000 claims description 6
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 6
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 6
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 6
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 6
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 229950005143 sitosterol Drugs 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 6
- ALSPKRWQCLSJLV-UHFFFAOYSA-N azanium;acetic acid;acetate Chemical compound [NH4+].CC(O)=O.CC([O-])=O ALSPKRWQCLSJLV-UHFFFAOYSA-N 0.000 claims description 5
- 206010020710 Hyperphagia Diseases 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 206010036067 polydipsia Diseases 0.000 claims description 4
- 208000022530 polyphagia Diseases 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 210000004926 tubular epithelial cell Anatomy 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 229940074774 glycyrrhizinate Drugs 0.000 claims 1
- 206010016766 flatulence Diseases 0.000 abstract description 3
- 241000255789 Bombyx mori Species 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 2
- 229940010454 licorice Drugs 0.000 abstract description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 70
- 241000700159 Rattus Species 0.000 description 59
- 230000003345 hyperglycaemic effect Effects 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 31
- 239000005720 sucrose Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 19
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 18
- 229960002632 acarbose Drugs 0.000 description 18
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 17
- 229930006000 Sucrose Natural products 0.000 description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- 229920002472 Starch Polymers 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 238000003304 gavage Methods 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 235000008429 bread Nutrition 0.000 description 7
- 239000004382 Amylase Substances 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000007670 refining Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101100011524 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MCO6 gene Proteins 0.000 description 4
- 210000000695 crystalline len Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000738 kidney tubule Anatomy 0.000 description 3
- 229940040461 lipase Drugs 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000008627 kidney hypertrophy Diseases 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910021487 silica fume Inorganic materials 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Insects & Arthropods (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
Abstract
A pharmaceutical composition for treating diabetes and preparation methods, quality control methods and uses thereof, said pharmaceutical composition is prepared by using silkworm shit and licorice as raw materials, it not only can reduce blood sugar, but also can improve flatulence.
Description
PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES AND
PREPARATION METHOD THEREOF
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition and its preparation method, especially relates to a pharmaceutical composition for treating diabetes, and its preparation method and quality control method.
BACKGROUD OF THE INVENTION
Incidence of Diabetes (diabetes) becomes increasingly in china and abroad, which seriously harms people's health and even their lives. At present, it is understood that there are more than 200 million diabetics in the worldwide, and 85% of them are elder diabetics. There are 30 million diabetics in china, only second to the United States, but increasing at an annual rate of 750,000 new patients. Therefore, diabetes has belonged to one of major difficult diseases in national 95" projects, but efficacy of anti-diabetic traditional Chinese medicine is presently not satisfactory, and Acarbose and other drugs commonly used for treating diabetes can cause flatulence, borborygmus and other side effects. Consequently, it is necessary to carry out research on prevention and treatment of diabetes.
SUMMARY OF INVENTION
One purpose of present invention is to provide a pharmaceutical composition for treating diabetes; another purpose of the present invention is to provide preparation method and quality control method of this composition.
The purposes of present invention can be implemented through the following technical schemes: Raw materials of this invention pharmaceutical composition consist of: Feculae Bombycis (silkworm excrement) 6000-8000 parts by weight Radix Glycyrrhizae (licorice) 100-200 parts by weight.
Preferably, raw materials of this invention pharmaceutical composition consist of: Feculae Bombycis 7150 parts by weight Radix Glycyrrhizae 137.5 parts by weight.
Preferably, raw materials of this invention pharmaceutical composition consist of: Feculae Bombycis 6l5Oparts by weight Radix Glycyrrhizae 187.Sparts by weight.
Preferably, raw materials of this invention pharmaceutical composition consist of: Feculae Bombycis 7850 parts by weight Radix Glycyrrhizae 117.5 parts by weight.
According to usual process by adding general adjuvant, this invention pharmaceutical composition is produced to tablet, capsule, powder, soft capsule, drop pill, honey pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection.
The preparation method of pharmaceutical composition of this invention can also comprise: Taking Feculae Bombycis, adding 50-70% ethanol at 2-6 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 1-3 times, each time 0.5-1.5 hours, filtering, combining the filtrates, recover ethanol, after the ethanol is removed, heating the filtrates up to concentrate or vacuum concentrated at a temperature below 80°C until the relative density of 0.95-1.10 (measured at the temperature 55°C), then obtaining concentrated solution, adding water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating up to concentrate the supernatant, or vacuum concentrating the supernatant at 80°C to obtain the thick paste A with the relative density of 1.00-1.15 (measured at the temperature 55°C), stand it by service; taking Radix Glycyrrhizae, adding 8-15 folds amount of Radix Glycyrrhizae with water, decocting 1-3 times, each time 1-3 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.00-1.15 (measured at a temperature 55°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process by adding general adjuvant, then they are produced to tablet, capsule, powder, soft capsule, drop pill, honey pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection, or Taking Feculae Bombycis, adding 50-70% ethanol at 2-6 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 1-3 times, each time 0.5-1.5 hours, filtering, combining the filtrates, recover ethanol, after the ethanol is removed, heating the filtrates up to concentrate or vacuum concentrated at a temperature below 80°C until the relative density of 0.95-1.10 (measured at the temperature 55°C), then obtaining concentrated solution, adding water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating up to concentrate the supematant, or vacuum concentrating the supernatant at 80°C to obtain the thick paste A with the relative density of 1.00-1.15 (measured at the temperature 55°C), stand it by service; taking Radix Glycyrrhizae, adding 8-15 folds amount of Radix Glycyrrhizae with water, decocting 1-3 times, each time 1-3 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.00-1.15 (measured at a temperature 55°C), stand it by service; combining the thick paste A and the thick paste B, adding an appropriate amount of fl-cyclodextrin or micro silica, spraying drying, adding an appropriate amount of hydroxypropyl cellulose (L-HPC) or other general adjuvant, blending, granulating, according to usual process by adding general adjuvant, then they are produced to tablet, capsule, powder, soft capsule, drop pill, honey pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection.
Preferably, the preparation method of pharmaceutical composition of this invention is: Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recover ethanol, after the ethanol is removed, heating the filtrates up to concentrate or vacuum concentrated at a temperature below 80°C until the relative density of 1.01-1.06 (measured at the temperature 55°C), then obtaining concentrated solution, adding same amount water and heating to boiling, cooling, placing overnight, then taking supematant A, heating up to concentrate the supernatant, or vacuum concentrating the supernatant at 80°C to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55°C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 55°C), stand it by service; combining the thick paste A and the thick paste B, adding fl-cyclodextrin or micro silica with amount of 20% Feculae Bombycis dry paste, spraying drying, adding hydroxypropyl cellulose (L-HPC) in amount of 1% drug powder, blending, according to usual process by adding general adjuvant, then they are produced to tablet, capsule, powder, soft capsule, drop pill, honey pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection.
Quality control method of this invention pharmaceutical composition includes one or more of following identification andlor content determination: Identification: A. Taking 0.4-0.6g pharmaceutical composition of this invention, adding 4-6 ml anhydrous ethanol, refluxing in 40-80 °C water bath for 20-40 minutes, placing and taking supernatant, evaporating it until 0.5-1.5 ml above water bath, that is test sample solution; furthermore, taking 13-sitosterol as reference substance, adding anhydrous ethanol for 0.0005-0.OOlSgIml solution, that is reference substance solution; according to thin layer chromatography test, sucking above two solutions 0.00 1- 0.003m1 respectively, pointing them on the same TLC plate of silica gel G respectively, developing, taking out, drying, 18-21:0.3-0.7 of chloroform: acetone as mobile phase, and spraying with 5% -15% phosphor-molybdic acid solution, heating in 100-110°C until visualize the chromatogram; the chromatogram produced by the test sample solution shows the same color spots as that displayed by the reference substance solution in their respectively corresponding areas; B. Identification by high-performance liquid chromatography, Using octadecylsilanized silica gel as packing; using methanol-(0.2mol I L) ammonium acetate -acetic acid = 50-70:30-50:0.5-1.5 as mobile phase; detection wavelength 250nm; theoretical plate number counted according to peak ammonium glycyrrhizinate is not less than 2000; weighing 0.005-0.015g mono-ammonium glycyrrhizinate reference compound accurately, putting it into 50m1 volumetric flask, dissolving by above mobile phase to the volume, shaking up, that is, 0.0001-0.0003g mono-ammonium glycyrrhizinate per ml, which is equivalent to 0.00019-0.00020g glycyrrhizic acid, that is reference substance solution; taking pharmaceutical compositions of this invention 1.0-3.Og, put it into 25 ml volumetric flask, adding 1 8-22m1 above mobile phase, deal with ultrasound for 20-40 minutes with power 250W, frequency of 50KHz, taking out and cooling, adding mobile phase to the volume, shaking up, centrifuging, taking the supernatant, that is test sample solution; accurately sucking reference substance solution and test sample solution 0.005-0.01 5ml respectively, injecting into liquid chromatogram instrument, test sample should be presented the same retention time peaks with the reference substance.
Content determination: An applicability test of chromatogram condition and system Using octadecylsilanized silica gel as packing; using a solution with acetonitrile-dimethyl formamide-sodium acetate(0.O25mollL)= 15-25: 0.1-1: 75-85 as mobile phase; detection wavelength is 390nm, theoretical plate number counted according to peak Pipecolic acid is not less than 2500; Weighing 0.004-0.006g Pipecolic acid reference compound accurately, put it into 50m1 volumetric flask, adding water to dilute to the volume, shaking up, measuring 0.5-1.5m1 the said solution accurately, putting it into 10m1 test tube with plug, adding 0.5-1. 5m1 water, adding 1 -3ml 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 1-3m1 sodium bicarbonate solution(0.5molIL), heating up in 60°C water bath for 0.5-1.5 hours, taking out, cooling, and transferring into lOmi volumetric flask, washing container with phosphate buffer solution (0.2molIL, pH7.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is reference compound solution; weighing 0.3-0.5g the pharmaceutical composition of present invention accurately, placing it in lOml test tube with plug, adding water, shaking up fully, heating up in 0-70°C water bath for 20-40 minutes, taking out, cooling, and transferring into lOml volumetric flask, washing container with water by several times, combining the washing solution into volumetric flask and adding water to volume, and shaking up; centrifuging 12000 rpm for 5-15 minutes, measuring 1-3ml the supernatant accurately, placing it into lOml test tube with plug, adding 1-3ml 2,4-acetonitrile dinitrofluorobenzene solution(0. 8%) and 1 -3ml sodium bicarbonate solution(0.5moIlL), heating up in 50-70°Cwater bath for 0.5-1.5 hours, taking out, cooling, and transferring into 1 Omi volumetric flask, washing container with phosphate buffer solution (0.2molIL, pH7.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is test sample solution, accurately sucking 0.004-0.OO6ml reference substance solution and 0.005-0.015m1 test sample solution respectively, injecting into liquid chromatogram instrument, determining, that is; Feculae Bombycis content in the pharmaceutical composition of this invention in dosage per day, counted according to Pipecolic acid (C6H11NO2), is not less than 0.0001-0.0003g.
Preferably, Quality control method of this invention pharmaceutical composition includes one or more of following identification andlor content determination: Identification: A. Taking 0.5g pharmaceutical composition of this invention, adding 5 ml anhydrous ethanol, refluxing in 60 °C water bath for 30 minutes, placing and taking supematant, evaporating it until 1 ml above water bath, that is test sample solution; furthermore, taking 13-sitosterol as reference substance, adding anhydrous ethanol for 0.00 lg/ml solution, that is reference substance solution; according to thin layer chromatography test, sucking above two solutions 0.OO2ml respectively, pointing them on the same TLC plate of silica gel G respectively, developing, taking out, drying, 19.5:0.5 of chloroform: acetone as mobile phase, and spraying with 10% phosphor-molybdic acid solution, heating in 105°C until visualize the chromatogram; the chromatogram produced by the test sample solution shows the same color spots as that displayed by the reference substance solution in their respectively corresponding areas; B. Identification by high-performance liquid chromatography, Using octadecylsilanized silica gel as packing; using methanol-(0.2mol I L) amrnonium acetate -acetic acid 60:40:1 as mobile phase; detection wavelength 250nm; theoretical plate number counted according to peak ammonium glycyrrhizinate is not less than 2000; weighing 0.Olg mono-ammonium glycyrrhizinate reference compound accurately, putting it into 50m1 volumetric flask, dissolving by above mobile phase to the volume, shaking up, that is, 0.0002g mono-ammonium glycyrrhizinate per ml, which is equivalent to 0.000 1 959g glycyrrhizic acid, that is reference substance solution; taking phannaceutical compositions of this invention 2g, putting it into 25 ml volumetric flask, adding 20m1 above mobile phase, deal with ultrasound for 30 minutes with power 250W, frequency of 50KHz, taking out and cooling, adding mobile phase to the volume, shaking up, centrifuging, taking the supematant, that is test sample solution; accurately sucking reference substance solution and test sample solution 0.Olml respectively, injecting into liquid chromatogram instrument, test sample should be presented the same retention time peaks with the reference substance.
Content determination: An applicability test of chromatogram condition and system Using octadecylsilanized silica gel as packing; using a solution with acetonitrile-dimethyl formamide-sodium acetate(0.O25molIL)= 21:0.5:79 as mobile phase; detection wavelength is 390nm, theoretical plate number counted according to peak Pipecolic acid is not less than 2500; Weighing 0.Olg Pipecolic acid reference compound accurately, putting it into 1 OOml volumetric flask, adding water to dilute to the volume, shaking up, measuring lml the said solution accurately, putting it into I Oml test tube with plug, adding im! water, adding 2m1 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 2ml sodium bicarbonate solution(0.5molIL), heating up in 60°C water bath for 1 hour, taking out, cooling, and transferring into lOmi volumetric flask, washing container with phosphate buffer solution (0.2molIL, pH7.0) by 3 times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is reference compound solution; weighing 0.4g the pharmaceutical composition of the present invention accurately, placing it in 1 Oml test tube with plug, adding 5m1 water, shaking up fully, heating up in 60°C water bath for 30 minutes, taking out, cooling, and transferring into lOmi volumetric flask, washing container with water by 3 times, combining the washing solution into volumetric flask and adding water to volume, and shaking up; centrifuging 12000 rpm for 10 minutes, measuring 2m1 the supernatant accurately, placing it into 1 Oml test tube with plug, adding 2m1 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 2ml sodium bicarbonate solution(0. 5mol!L), heating up in 60°Cwater bath for 1 hour, taking out, cooling, and transferring into 1 0m1 volumetric flask, washing container with phosphate buffer solution (0.2mol!L, pH7.0) by 3 times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is test sample solution, Accurately sucking 0.005m1 reference substance solution and 0.Olml test sample solution respectively, injecting into liquid chromato gram instrument, determining, that is; Feculae Bombycis content in the pharmaceutical composition of this invention in dosage per day, counted according to Pipecolic acid (C6H11N02), is not less than 0.0002g.
Iii this invention, said relationship between weight parts and volume parts is g / ml.
Quality control methods of pharmaceutical compositions of this invention can be applied to a variety of dosage forms of compositions, such as tablets, capsules, powders, soft capsules, dipping pills, honey pills, granules, honey refining pastes, slow-release preparations, rapid-release preparations, controlled-release preparations, oral liquid preparations, or injection preparations, and other clinically acceptable dosage forms. Because different dosage forms of preparations contain same considerable amount of crude drug, in quality control of various dosage forms, selected samples can be converted into relatively uniform dose of crude drug congruously. Preparation per unit is corresponding to amount of crude drug 65g (daily dose) in the quality control method, and it can also be preparation per tablet, per piece, per injection, per pill, and so on.
DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph depicting influence of MC for blood glucose of normal mice after sucrose feeding; Figure 2 is a graph depicting influence of MC for blood glucose of normal mice after starch feeding; Figure 3 is a graph depicting influence of MC for blood glucose of alloxan-induced hyperglycemic mice after sucrose feeding; Figure 4 is a graph depicting influence of MC for blood glucose of alloxan-induced hyperglycemic mice after starch feeding; Figure 5 is a graph depicting influence of MC for blood glucose of healthy volunteers after steamed bread feeding; Figure 6 is a chart depicting influence of MC for urine glucose of alloxan-induced hyperglycemic rats; Figure 7 is a chart depicting influence of MC for kidney weight/body mass index of alloxan-induced hyperglycemic rats; Figure 8 is a chart depicting kidney, glomerulus and renal tubules of normal rats show no lesion X50 Figure 9 is a chart depicting that renal tubules epithelial cells of some alloxan-induced hyperglycemic rats group became swell with vacuolar appearance x50; Figure 10 is a chart depicting renal tubules of MC rat group rats show no significant lesion X50 Experiments prove that pharmaceutical composition of this invention is better than raw material drugs used respectively. In addition to a hypoglycemic effect, two drugs combined have a synergistic effect, which is to improve on intestinal tympanites.
After administrating this pharmaceutical composition for 4 weeks chronically, it can significantly improve the alloxan-induced hyperglycemic rats on common symptoms of polydipsia or polyphagia; decrease blood glucose and serum fructosamine significantly; decrease serum cholesterol markedly and also triglyceride levels; decrease serum NAG-ase activity markedly, and explain to improve on microvascular complications; decrease sorbitol content in sciatic nerve markedly, and clue to improve on chronic neuropathy of diabetes; increase GSH content in red blood cell, and enhance body's antioxidant capacity; lower kidney weight and body mass index markedly, reduce serum creatinine levels, relief glycogen deposition in renal tubular epithelial cells; in addition, inhibit cx-glucosidase activity of the pharmaceutical compositions of this invention in vitro is stronger, while free for a-amylase. It explain the pharmaceutical compositions of this invention can reduce blood sugar elevation induced by disaccharide hydrolysis absorb into blood, while the incidence of gastrointestinal side effects is lower than similar products.
The following experiments and examples are for further explanation, but not limiting the present invention.
The following experiments 1-8 use all following test medicines and experimental animals.
Test medicines: 1. Extract powder of the said pharmaceutical composition (obtain in experiment 1), abbreviated as MC, offered by Institute of Materia Medica Chinese Academy of Medical Sciences, batch number: 96102, per gram of extract powder is equivalent to 16.7g crude drug; MC extract powder dissolved with water; 2. Acarbose: produced by Bayer pharmaceutical, Germany, batch number: 264086D.
Animals: Kunming mice, Beijing animal quality control file number (1994), No. 029; Wistar rats, Beijing animal quality control file number (1994), No. 030, were both purchased from breeding plants of Chinese Academy of Medical Sciences Institute, mice 22-25g, rat 180-250g, Sex: Male, animal number in each group: 10.
Alloxan-induced hyperglycemic mouse and rat models: normal animals are injected alloxan intravenously (mice 90-100 mg / kg, rats 45-50 mg / kg), predicted blood glucose (glucose oxidase method) after administering 72 hours, animals which are their blood glucose values over 11.1 mmol / L are selected for experiments.
EXPERIMENT 1: influence of MC for blood glucose elevation of normal mice after sucrose feeding Normal mice are divided into 5 groups, 10 mice each group, are fasted overnight before the experiment, a group of oral sucrose solution 4.0 g I kg as a control group, a group of oral sucrose and Acarbose 10 mg I kg as the positive control group. The remaining three groups respectively, with oral sucrose and different doses of MC 0.45 g /kg, 0.9 g I kg, 1.8 g I kg. Determine blood glucose values at 0 mm and 30 mm, 60 mm, 1 20mm after the administration, results are shown in Figure 1, Table 1: Table 1. Influence of MC for Peak blood glucose, Peak time and AUC of normal mice after sucrose feeding (mean�SD, n=10) Group Peak blood Peak time( mm.) AUC( mmol/L.hr) glucose ( mmol/L) Control 9.0 � 1.6 30 12.9 � 2.8 MC 0.45 7.6 � 0.6 60 12.2 � 1.9 MC 0.9 6.8 � 1.9 * 60 10.6 � 3.0 MCI8 54+13** 60 92+22** 5.O�1.6*** 120 9.2�2.7** Acarbose AUC is area under blood glucose curve; compared with control group * P<0.05,** P<0.01, p<O.OO1; MC dose is g/kg0 Experimental results show that, MC can reduce blood glucose AUC (area under curve) of normal mice after sucrose feeding, furthermore the peak blood glucose decreased significantly and shift back, which basically identical for the role of Acarbose, and show a certain dose-effect relationship.
EXPERIMENT 2: influence of MC for blood glucose elevation of normal mice after starch feeding normal mice are divided into five groups, 10 mice each group, are fasted overnight, a group of soluble starch 3.0 g / kg by gavage as a control group, a group of oral sucrose and Acarbose 10 mg / kg as the positive control group. The remaining three groups respectively, with oral sucrose and different doses of MC (0.45 g / kg, 0.9 g I kg, 1.8 g I kg). Determine blood glucose values at 0 mm and 30 mm, 60 mm, 1 20mm after the administration, results are shown in Figure 2, Table 2: Table 2. Influence of MC for Peak blood glucose, Peak time and AUC of normal mice after starch feeding (mean�SD,n=10) Group Peak blood glucose Peak time( mm.) AUC( mmol/L.hr) (mmol/L) Control 9.4�2.1 30 12.0�2.6 MCO.45 6.8�1.4** 60 10.6�1.6 MCO.9 6.2�0.6** 60 10.3�1.6 MC1.8 4.4�O.4*** 120 8.3�1.4*** Acarbose 4.2 �0.5 *** 30 8.1 � 1.1 AUC is area under blood glucose curve compared with control group * P<0.05,** P<0.0l, p<O.OOl; MC dose is g/kg0 Results show that, MC can make the peak blood glucose decreased significantly and shift back after of normal mice after starch feeding, and reduce blood glucose AUC markedly, and show a certain dose-effect relationship.
EXPERIMENT 3: influence of MC for blood glucose elevation of normal mice after glucose feeding Normal mice are divided into 4 groups, 10 mice each group, are fasted overnight, a group of glucose 4.0 g / kg by gavage as a control group, a group of glucose and Acarbose 10 mg / kg by gavage as the positive control group. The remaining two groups respectively, with glucose and different doses of MC (0.45 g / kg, 1.8 g / kg) by gavage. Determine blood glucose values at 0 mm and 30 mm, 60 mm, 120mm after the administration, results are shown in Table 3: Table 3. Influence of MC for Peak blood glucose, Peak time and AUC of normal mice after glucose feeding (mean�SD, n=10) Group Peak blood Peak Ume( mm.) glucose ( mmol/L) AUC( mmol/L.hr) Control 10.2�1.9 30 14.6�2.1 MC 0.45 9.7 � 1.3 30 14.2 � 1.8 MC 1.8 9.4 � 1.9 30 14.8 � 1.7 Acarbose 10.7 �2.4 30 15.1 �2.6 AUC is area under blood glucose curve MC dose is g/kg0 Results show that, MC is identical for Acarboset, has no significant influence for blood glucose elevation of normal mice after glucose feeding. It explains that this composition does not directly affect intestinal absorption for glucose.
EXPERIMENT 4: Influence of MC for blood glucose elevation of alloxan-induced hyperglycemic mice after sucrose feeding Alloxan-induced hyperglycemic mice are divided into 5 groups, 10 mice each group, are fasted overnight, a group of sucrose 4.0 g / kg by gavage as a control group, a group of sucrose and Acarbose 10 mg I kg by gavage as the positive control group.
The remaining three groups respectively, with sucrose and different doses of MC (0.6 g I kg, 1.2 g I kg, 1.8 g / kg) by gavage. Determine blood glucose values at 0 mm and 30 mm, 60 mm, 1 20mm after the administration, results are shown in Figure 3, Table 4: Table 4. Influence of MC for Peak blood glucose, Peak time and AUC of alloxan-induced hyperglycemic mice after sucrose feeding (mean�SD,n=10) Group Peak blood glucose Peak time(min.) AUC( mmol/L.hr) (mmol/L) Control 22.6 � 1.7 30 39.0 � 4.2 MCO6 193+27** 60 342+48* MC 1 2 17 1+1 3 *** 60 30 8+2 8 MC 1.8 14.8�1.8 *** 60 28.2� 4.8 *** Acarbose 17.3�2.6 *** 60 30.7� 4.3 AUC is area under blood glucose curve; compared with control group * P<0.05,** P<0.01, p<O.OO1; MC dose is g/kg0 Experimental results show that, different doses of MC can significantly reduce blood glucose elevation of alloxan-induced hyperglycemic mice after sucrose feeding, reduce blood glucose AUC significantly, make peak blood glucose value shift back, MC is identical for Acarbose at effect.
EXPERIMENT 5: Influence of MC for blood glucose elevation of alloxan-induced hyperglycemic mice after starch feeding Alloxan-induced hyperglycemic mice are divided into 5 groups, 10 mice each group, are fasted overnight, a group of starch 3.0 g / kg by gavage as a control group, a group of starch and Acarbose 10 mg / kg as the positive control group. The remaining three groups respectively, with starch and different doses of MC (0.6 g I kg, 1.2 g / kg, 1.8 g / kg). Determine blood glucose values at 0 mm and 30 mm, 60 mm, 1 20mm after the administration, results are shown in Figure 4, Table 5: Table 5. Influence of MC for Peak blood glucose, Peak time and AUC of alloxan-induced hyperglycemic mice after starch feeding (mean�SD,n=10) Group Peak blood glucose Peak time(min.) (mmol/L) AUC( mmol/L.hr) Group 24.4 � 1.3 30 40.6 � 4.4 Control 23.0 � 2.9 60 36.6 � 5.9 MCO.6 213+31** 60 359+46* MC 1 2 19 3+2 2 60 32 9+3 9 MC 1.8 17.0�2.9 *** 60 31.3�5.9 AUC is area under blood glucose curve;compared with control group * P<0.05, P<0.0l, p<O.OOl; MC dose is g/kg0 Experimental results show that, different doses of MC can inhibit blood glucose elevation of alloxan-induced hyperglycemic mice after starch feeding, reduce blood glucose AUC, make peak blood glucose value shift back.
EXPERIMENT 6: Influence of MC for blood glucose of healthy volunteers after steamed bread feeding 7 volunteers (the Institute staff), 2 males and 5 females, aged 25-62 years. In first test, after fasting, each person ate 100 g steamed bread (offered by canteen of the Institute) as self-control; in second test, randomly, 4 volunteers take MC 1.5 g / person, 3 persons take MC 3.0 g I person, and ate 100 g steamed bread at one time, Determine blood glucose values at fasting (0 mm) and 30 mm, 60 mm, 120 mm after ate steamed bread. Interval of two experiments is 1 week, and the results shown in Figure 5 and
Table 6.
Table 6. Influence of MC for Peak blood glucose, Peak time and AUC of healthy volunteers after steamed bread feeding (mean�SD) High dose(3.0 g/person) Low dose( 1.5 gI person) Before After Before After administration administration administration administration n 3 3 4 4 Peak blood 6.8� 1.4 4.6�0.5 * 6.5� 1.5 5.4 � 0.9 * glucose (mmol/L) Peak time (mm.) 30 60 30 60 AUC(mmol/L.hr) 12.2� 1.9 8.8�0.5.,. 11.5 �3.1 10.0�1.2 AUC is area under blood glucose curve;Compared after and before with themseif * P<0.05, .T. P 0.05 The preliminary results show, MC can reduce peak blood glucose value OF healthy volunteers after steamed bread feeding, reduce blood glucose AUC, make blood glucose peak value shift back, and show dose-effect relationship.
EXPERIMENT 7: influence of MC for urine glucose of alloxan-induced hyperglycemic rats Three groups of alloxan-induced hyperglycemic rats, 10 rats each group. A group ate high-sucrose diet as hyperglycemic control, the second and third groups ate high-sucrose diet with different doses of MC (equivalent to a dose of 0.6 g /kg, 1.2 g / kg) respectively. The fourth group is 10 normal rats as control group, ate normal diet.
After two weeks, collect urine by metabolic cages, measure urine sugar levels of 6 hours, simultaneously, collect urine of the fourth group, normal rat, measure it as a comparison, the results are shown in Figure 6.
The results show that: normal rats were not detected glucose in urine, MC can significantly reduce urine sugar levels in alloxan-induced hyperglycemic rats, and it shows a certain dose-effect relationship.
EXPERIMENT 8: Influence of MC for general conditions, blood glucose, blood lipids, fructosamine, serum N-acetyl-/3-D glucosaminidase (short for NAG-ase) activity, sorbitol content in organization, red GSH content in blood cell, urea nitrogen and creatinine levels in serum, as well as influences of renal pathological changes, and so on of alloxan-induced hyperglycemic rats Three groups of alloxan-induced hyperglycemic rats, 10 rats each group. A group ate high-sucrose diet as hyperglycemic control, the second and third group ate high-sucrose diet with different doses of MC (equivalent to a dose of 0.6 g / kg, 1.2 g I kg) respectively. The fourth group is 10 normal rats as control group, eat normal diet.
Observe the general condition of animals every day, and record food and water intake.
After 4 weeks, the animals were killed to take blood, crystalline lens, sciatic nerve and other organizations, measure blood glucose, blood lipids, fructosamine, serum NAG activity, sorbitol content in organization, GSH content in red blood cell, urea nitrogen and creatinine levels in serum, and the other biochemical indicators, and observe renal pathological changes, the results are as follow: 1. Changes of food and water intake, Table 7: Table 7. Influence of MC for food and water intake of alloxan-induced hyperglycemic rats; (mean�SD) Group Food intake( glratlday) Water intake( ml! rat/day) Normal rats 22.6 � 3.3 19.5 � 3.4 Hyperglycemic rats 125.3 � 15.1 118.6 � 19.6 MCO6 990+60** 612+112*** MC 1.2 179.8� 12.1 *** 39449*** Compared with hyperglycemic rats, ** P<0.01, P<0.001 MC dose is glkg.
2. Influence of MC for blood glucose, fructosamine of alloxan-induced hyperglycemic rats, Table 8; Fructosamine is an aldehyde-ketone condensation compound format through molecular rearrangements in the process of nonenzymatic glycosylation between plasma protein (albumin mainly) and glucose molecules. Since the stability of albumin concentration in the body, so serum fructosamine level is also stable relatively. It can reflect the blood glucose levels within 1-2 weeks.
Table 8. Influence of MC for blood glucose, fructosamine of alloxan-induced hyperglycemic rats ( mean � SD, n=10) Group blood glucose ( mmol!L) Fructosamine no fasting fasting (mmol!L) Normal 5.4 � 0.2 3.4 � 0.5 1.60 � 0.12 25.9�3.6 16.5�2.1 2.64�0.16 Hyperglycemic rats MCO6 191+34*** 104+35*** 220+024*** MC 1.2 10.9�4.4 *** 8.3 � 3.7 *** 2.00 � 0.16 Compared with hyperglycemic rats, P<0.001; MC dose is g/kg.
3. Influence of MC for blood lipids, Table 9: Animals, which have high blood sugar, oflen have high blood lipids. Reducing blood glucose can improve high blood lipids. Blood lipids are determined by Enzyme method, kit purchased from Beijing Biosino Bio-technology & science INC.
Table 9. Influence of MC for blood lipids of alloxan-induced hyperglycemic rats; (mean�SD, n=l0) Group Blood lipids( mmol/L) Triglycerides Total cholesterol Normal rats 0.98 � 0.21 2.54 � 0.21 Hyperglycemic rats 1.83 � 1.00 2.78 � 0.24 MCO.6 1.70�0.58 2.31 �0.17* MCI.2 1.16�0.30.. 2.44�0.28* Compared with hyperglycemic rats, * P<0.05, 4 P0.05 MC dose is g/kg 4. Influence of MC for serum NAG-ase activity, Table 10: NAG enzyme is a lysosomal enzyme which present in renal parenchyma widely, and has closely relation with urinary albumin excretion and retinal microangiopathy degree, and it is a sensitive indicator of microangiopathy. With the microvascular disease increases, NAG activity increases.
Table 10. Influence of MC for serum NAG-ase activity of alloxan-induced hyperglycemic rats (mean�SD n=10) Group Serum NAG-ase ( lu) Normal rats 48.3 � 5.9 Hyperglycemic rats 88.0 � 28.1 MC 0.6 67.5 � 17.0 MC1.2 52.9�13.7** Compared with hyperglycemic rats, ** P<0.01; MC dose is g/kg 5. Influence of MC for sorbitol content in crystalline lens and sciatic nerve of alloxan-induced hyperglycemic rats, Table 11: Sorbitol pathway is closely related with occurrence and development of chronic complications of diabetes. Increased level of tissue sorbitol content can directly reflect the activity metabolism level of sorbitol channel. Determine it with sodium arsenite-chromotropic acid method.
Table 11. Influence of MC for sorbitol content in crystalline lens and sciatic nerve of alloxan-induced hyperglycemic rats (mean � SD, n=1O) Group Sorbitol( j.imol/g tissue) Crystalline lens sciatic nerve Normal rats 1.35�0.12 2.44�0.23 Hyperglycemic rats 3.56 � 0.78 9.54 � 1.93 MCO6 347+055 571+102*** MCI.2 3.39�0.82 4.15�1.11 Compared with hyperglycemic rats, P<0.OO1; MC dose is g/kg 6. Influence of MC for reduced glutathione (GSH) content in red blood cell on alloxan-induced hyperglycemic rats, Table 12: Free radical theory is one of major theories about occurrence and development of some diabetic chronic complications explained by molecular biology level. In high blood sugar state, GSH levels of red blood cell often low, it can reflect the body's ability to withstand free radical damage.
Table 12. Influence of MC for GSH in red blood cell of alloxan-induced hyperglycemic rats (mean � SD, n=10) Group GSH( mmol/L) P value Normal rats 0.95 � 0.16 Hvoeralvcemic 0.61 � 1.16 MCO.6 1.02�0.19 <0.01 MC 1.2 1.322 � 0.32 <0.01 P value is compared with hyperglycemic rats; MC dose is g/kg 7. Influence of MC for kidney weight/body mass index of alloxan-induced hyperglycemic rats, Figure 7: Diabetic kidney hypertrophy and hyperfiltration phenomenon are the earliest changes appearing in renal pathophysiology. Whether or not control diabetic kidney hypertrophy is often one of symbols that effectiveness of treatment of this disease.
8. Influence of MC for kidney serum urea nitrogen and creatinine levels of alloxan-induced hyperglycemic rats (Table 13): Determine serum urea nitrogen and creatinine levels can speculate changes of renal function. Serum urea nitrogen and creatinine levels rise, then it reflect renal dysfunction. Method uses reagent kit of Beijing Biosino Bio-technology & science INC.
Table 13. Influence of MC for kidney serum urea nitrogen and creatinine levels of alloxan-induced hyperglycemic rats (mean � SD, n=10) Group Urea nitrogen( mmol/L) Creatinine ( jtmoI/L) Normal rats 6.64�1.36 47.74� 6.19 Hyperglycemic 5.39 � 0.71 84.86� 14.14 rats MC 0.6 5.75 � 0.75 76.91� 23.87 MC 1.2 5.82 � 1.39 53.04� 13.26 * Compared with hyperglycemic rats * P<0.01; MCdose is g/kg 9. Influence of MC for renal pathological changes of alloxan-induced hyperglycemic rats Experimental rat kidney in each group is 10% fixed with formalin, regular slices, stained with hematoxylin eosin, observed by light microscope. Kidney structure of normal rat is normal (see Figure 8), not seen in any lesions. Part of renal epithelial cells of kidney tubules of hyperglycemic rats are swollen and vacuolar, and after their intracellular glycogen has been dissolved during production process, membrane is visible clearly (see Figure 9); kidney tubules of MC rats isn't observed such changes (see Figure 10). Glycogen nephrosis causes by increasing blood glucose absorption of glomerular epithelial cells when through renal tubules. After reduction of blood glucose and urine glucose, other disorders can be reduced. Experiment shows that, MC can improve lesions of kidney tubules, while reduce blood and urine glucose.
The experimental results show that, after long-term (4 weeks) administration, MC can significantly improve on polydipsia or polyphagia and other general conditions of alloxan-induced hyperglycemic rats; decrease significantly blood glucose and serum fructosamine; decrease serum cholesterol levels significantly, reduce serum triglyceride levels; also decrease serum NAG activity significantly, which indicates that it has an improvement for microvascular complications; reduce sorbitol content in sciatic nerve significantly, which suggests that it can improve chronic neurological disease of diabetes; increase GSH content in red blood cell, enhance the body's antioxidant ability; also reduce kidney weight/body mass index significantly, reduce serum creatinine levels, relieve glycogen deposition of renal tubular epithelial cells.
Experimental 9: Experiment in vitro of pharmaceutical composition prepared in example 1 1. Test drugs: test sample: pharmaceutical composition prepared in example 1, short for MC; positive control drug: Acarbose, Orlistat.
2. Experimental animals: normal wistar rats, 250-300 g, used to extract intestinal a-glucosidase.
3. Methods and Results: (1) Inhibit effect of MC for a-glucosidase With sucrose or maltose as substrate and Acarbose as a positive control, measure inhibition effect of MC for a-sucrose and maltose enzyme activity in rat intestinal, calculate IC50; with starch as substrate, Acarbose as a positive control, measure inhibition effect of MC for a-amylase activity, the results are shown in Table 14: Table 14. inhibition in vitro IC50 ( pg!ml) of MC for a-glucosidase Sample a-sucrase a-maltase a-amylase MC 2.53 4.05 >100 Acarbose 0.255 0.076 0.80 The results show that: MC has strong inhibitory activity on a-glucosidase in vitro, 1C50 of a-sucrase and maltase are 2.53 pg / ml and 4.05 g / ml; and it has no inhibitory effect on a-amylase activity.
(2) Inhibit effect of MC for lipase activity With triolein as substrate and Orlistat as a positive control, test samples MC response to porcine pancreatic lipase and lipoprotein lipase respectively, determine inhibitory activity of sample to lipase, by release rate of oleic acid released from triolein. The results are shown in Table 15: Table 15. Inhibitory rate of MC for lipase activity Terminal concentration Sample (pg/mi) Pancreatic lipase Lipoprotein lipase MC 10 0 0 Oriistat 10 100% 100% The results show that MC almost no inhibitory effect on lipase.
4. Experimental result: Experimental results show that, samples of MC have a very strong inhibitory effect on a-sucrose and a-maltase activity, and 1C50 are 2.53 pg / ml and 4.05 pg / ml respectively; do not inhibit a-amylase. It shows that MC only inhibit disaccharide hydrolase without inhibiting a-amylase activity, thus it greatly reduces amount of starch and oligosaccharides without fully hydrolyzed into intestinal bottom end, only part remnant disaccharide into intestinal bottom end, reduce hydrolyzed disaccharide absorbed into blood, make blood glucose elevation, their incidence of gastrointestinal side effects is lower than Acarbose. MC has no inhibitory effect on lipase, it shows that MC can not directly affect fat absorption from intestine.
The following examples can entirely achieve efficacies in above experiments.
EMBODIMENTS
EXAMPLE 1: PREPARATION OF CAPSULE Feculae Bombycis 7.15kg Radix Glycyrrhizae 0.1375kg Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hours, filtering, combining the filtrates, recovering ethanol, concentrating at a temperature 55°C, gaining concentrated solution of the relative density of 1.01-1.06, adding same amount water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating the supematant to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55°C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 55°C), stand it by service; combining the thick paste A and the thick paste B, adding 13-cyclodextrin with amount of 20% Feculae Bombycis dry paste, spraying drying, add hydroxypropyl cellulose (L-RPC) in amount of 1% drug powder, blending, drying, granulating, whole grain, putting into capsules, obtaining 1000 capsules, 2-4 tablets each time, three times daily.
EXAMPLE 2: PREPARATION OF TABLET Feculae Bombycis 7.15kg Radix Glycyrrhizae 0.1375kg taking above two crude drugs, according to usual process, adding general adjuvant,
producing tablet.
EXAMPLE 3: PREPARATION OF GRANULE Feculae Bombycis 6.15kg Radix Glycyrrhizae 0.1875kg taking above two crude drugs, according to usual process, adding general adjuvant, producing granule.
EXAMPLE 4: PREPARATION OF PILL Feculae Bombycis 7.85kg Radix Glycyrrhizae 0.1175kg taking above two crude drugs, according to usual process, adding general adjuvant, producing pill.
EXAMPLE 5: PREPARATION OF HONEY REFINING PASTE Feculae Bombycis 7.15kg Radix Glycyrrhizae 0.1375kg taking above two crude drugs, according to usual process, adding general adjuvant, producing honey refining paste.
EXAMPLE 6: PREPARATION OF ORAL LIQUID PREPARATION Feculae Bombycis 6.15kg Radix Glycyrrhizae 0.1875kg taking above two crude drugs, according to usual process, adding general adjuvant, producing oral liquid preparation.
EXAMPLE 7: PREPARATION OF INJECTION Feculae Bombycis 7.85kg Radix Glycyrrhizae 0.1175kg taking above two crude drugs, according to usual process, adding general adjuvant, producing injection.
EXAMPLE 8: Identification and content determination methods of the pharmaceutical composition capsule Identification: A. Taking 0.Sg capsule content of this invention pharmaceutical composition prepared in Example 1, adding 5 ml anhydrous ethanol, refluxing in 60°C water bath for 30 minutes, placing and taking supematant, evaporating it until 1 ml above water bath, that is test sample solution; furthermore, taking /3-sitosterol as reference substance, adding anhydrous ethanol for 0.00 ig/mI solution, that is reference substance solution; according to thin layer chromatography test, sucking above two solutions 0.002m1 respectively, pointing them on the same TLC plate of silica gel G respectively, developing, taking out, drying, 19.5:0.5 of chloroform: acetone as mobile phase, and spraying with 10% phosphor-molybdic acid solution, heating in 105°C until visualize the chromatogram; the chromatogram produced by the test sample solution shows the same color spots as that displayed by the reference substance solution in their respectively corresponding areas; B. Identification by high-performance liquid chromatography, Using octadecylsilanized silica gel as packing; using methanol-(0.2mol / L) ammonium acetate -acetic acid = 60:40:1 as mobile phase; detection wavelength 250nm; theoretical plate number counted according to peak ammonium glycyrrhizinate is not less than 2000; weighing 0.Olg mono-ammonium glycyrrhizinate reference compound accurately, putting it into 5Oml volumetric flask, dissolving by above mobile phase to the volume, shaking up, that is, 0.0002g mono-ammonium glycyrrhizinate per ml, which is equivalent to 0.0001959g glycyrrhizic acid, that is reference substance solution; taking 2g capsule content of this invention pharmaceutical compositions prepared in Example 1, putting it into 25 ml volumetric flask, adding 20m1 above mobile phase, deal with ultrasound for 30 minutes with power 250W, frequency of 50KHz, taking out and cooling, adding mobile phase to the volume, shaking up, centrifuging, taking the supernatant, that is test sample solution; Accurately sucking reference substance solution and test sample solution 0.005m1 respectively, injecting into liquid chromatogram instrument, test sample should be presented the same retention time peaks with the reference substance.
Content determination: An applicability test of chromatogram condition and system Using octadecylsilanized silica gel as packing; using a solution with acetonitrile-dimethyl formamide-sodium acetate(0.O25molIL)= 21:0.5:79 as mobile phase; detection wavelength is 390nm, theoretical plate number counted according to peak Pipecolic acid is not less than 2500; Weighing 0.Olg Pipecolic acid reference compound accurately, putting it into 1 OOml volumetric flask, adding water to dilute to the volume, shaking up, measuring lml the said solution accurately, putting it into 1 Omi test tube with plug, adding imi water, adding 2m1 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 2m1 sodium bicarbonate solution(0.5molIL), heating up in 60°C water bath for 1 hour, taking out, cooling, and transferring into 1 Omi volumetric flask, washing container with phosphate buffer solution (0.2mollL, pH7.0) by 3 times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is reference compound solution; accurately weighing 0.4g capsule content of this invention pharmaceutical composition prepared in Example 1, placing it in lOml test tube with plug, adding 5m1 water, shaking up fully, heating up in 60°C water bath for 30 minutes, taking out, cooling, and transferring into lOml volumetric flask, washing container with water by 3 times, combining the washing solution into volumetric flask and adding water to volume, and shaking up; centrifuging 12000 rpm for 10 minutes, measuring 2ml the supernatant accurately, placing it into 1 Omi test tube with plug, adding 2m1 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 2m1 sodium bicarbonate solution(0.5molIL), heating up in 60°Cwater bath for 1 hour, taking out, cooling, and transferring into lOmi volumetric flask, washing container with phosphate buffer solution (0.2mol/L, pH7.0) by 3 times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is test sample solution, Accurately sucking 0.005m1 reference substance solution and 0.Olml test sample solution respectively, injecting into liquid chromatogram instrument, determining, that is; dosage per day for the pharmaceutical composition of this invention is 0.5g, then Feculae Bombycis content counted according to Pipecolic acid (C6H11N02), is not less than 0.0018g.
EXAMPLE 9: Identification method of the pharmaceutical composition powder A. Taking 0.5g pharmaceutical composition powder of this invention, adding 6 ml anhydrous ethanol, refluxing in 40°C water bath for 40 minutes, placing and taking supernatant, evaporating it until 0.5 ml above water bath, that is test sample solution; furthermore, taking 3-sitosterol as reference substance, adding anhydrous ethanol for 0.0015g!ml solution, that is reference substance solution; according to thin layer chromatography test, sucking above two solutions 0.00 imi respectively, pointing them on the same TLC plate of silica gel G respectively, developing, taking out, drying, 21:0.3 of chiorofonri: acetone as mobile phase, and spraying with 15% phosphor-molybdic acid solution, heating in 100°C until visualize the chromatogram; the chromatogram produced by the test sample solution shows the same color spots as that displayed by the reference substance solution in their respectively corresponding areas; B. Identification by high-performance liquid chromatography, Using octadecylsilanized silica gel as packing; using methanol-(0.2mol / L) ammonium acetate -acetic acid = 50:50:0.5 as mobile phase; detection wavelength 250nm; theoretical plate number counted according to peak ammonium glycyrrhizinate is not less than 2000; weighing 0.005g mono-ammonium glycyrrhizinate reference compound accurately, putting it into 50m1 volumetric flask, dissolving by above mobile phase to the volume, shaking up, that is, 0.0003g mono-ammonium glycyrrhizinate per ml, which is equivalent to 0.00019g glycyrrhizic acid, that is reference substance solution; taking 3.Og pharmaceutical composition powder of this invention, putting it into 25 ml volumetric flask, adding 1 8m1 above mobile phase, deal with ultrasound for 20 minutes with power 250W, frequency of 50KHz, taking out and cooling, adding mobile phase to the volume, shaking up, centrifuging, taking the supematant, that is test sample solution; accurately sucking reference substance solution and test sample solution 0.01 Sml respectively, injecting into liquid chromatogram instrument, test sample should be presented the same retention time peaks with the reference substance.
EXAMPLE 10: Content determination method of the pharmaceutical composition granule An applicability test of chromatogram condition and system Using octadecylsilanized silica gel as packing; using a solution with acetonitrile-dimethyl formamide-sodium acetate(O.O25molIL)= 15:1:75 as mobile phase; detection wavelength is 390nm, theoretical plate number counted according to peak Pipecolic acid is not less than 2500; Weighing 0.006g Pipecolic acid reference compound accurately, putting it into 5Oml volumetric flask, adding water to dilute to the volume, shaking up, measuring 0.5m1 the said solution accurately, putting it into lOmi test tube with plug, adding 1.5m1 water, adding imi 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 3m1 sodium bicarbonate solution(0.5mollL), heating up in 60°C water bath for 0.5 hour, taking out, cooling, and transferring into 1 Omi volumetric flask, washing container with phosphate buffer solution (0.2molIL, p117.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is reference compound solution; accurately weighing O.5g granule of this invention pharmaceutical composition, placing it in lOm! test tube with plug, adding proper amount water, shaking up fully, heating up in 50°C water bath for 40 minutes, taking out, cooling, and transferring into 1 Omi volumetric flask, washing container with water by several times, combining the washing solution into volumetric flask and adding water to volume, and shaking up; centrifuging 12000 rpm for 5 minutes, measuring 3m1 the supernatant accurately, placing it into lOmi test tube with plug, adding imi 2,4-acetonitrile dinitrofluorobenzene solution(0. 8%) and 3m! sodium bicarbonate solution(0. 5molIL), heating up in 50°Cwater bath for 1.5 hour, taking out, cooling, and transferring into lOmi volumetric flask, washing container with phosphate buffer solution (0.2mo!!L, pH7.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is test sample solution, Accurately sucking 0.004m1 reference substance solution and 0.01 5m1 test sample solution respectively, injecting into liquid chromatogram instrument, determining, that is; dosage per day for the pharmaceutical composition of this invention is 0.5g. then Feculae Bombycis content counted according to Pipecolic acid (C6H11N02), is not less than 0.00 18g.
EXAMPLE 11: Identification and content determination methods of the pharmaceutical composition tablet Identification: A. Taking 0.5g tablet of this invention pharmaceutical composition prepared in Example 2, adding 5g anhydrous ethanol, refluxing in 60 °C water bath for 30 minutes, placing and taking supematant, evaporating it until 1 ml above water bath, that is test sample solution; furthermore, taking j3-sitostero! as reference substance, adding anhydrous ethanol for O.OOlg/ml solution, that is reference substance solution; according to thin layer chromatography test, sucking above two solutions 0.002m1 respectively, pointing them on the same TLC plate of silica gel G respectively, developing, taking out, drying, 19.5:0.5 of chloroform: acetone as mobile phase, and spraying with 10% phosphor-molybdic acid solution, heating in 105°C until visualize the chromatogram; the chromatogram produced by the test sample solution shows the same color spots as that displayed by the reference substance solution in their respectively corresponding areas; Content determination: An applicability test of chromatogram condition and system Using octadecylsilanized silica gel as packing; using a solution with acetonitrile-dimethyl formamide-sodium acetate(0.025mo1!L)= 21:0.5:79 as mobile phase; detection wavelength is 390nm, theoretical plate number counted according to peak Pipecolic acid is not less than 2500; Weighing 0.005g Pipecolic acid reference compound accurately, putting it into 50m1 volumetric flask, adding water to dilute to the volume, shaking up, measuring imi the said solution accurately, putting it into lOml test tube with plug, adding imi water, adding 2ml 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 2 parts by volume of sodium bicarbonate solution(0.5mol/L), heating up in 60°C water bath for 1 hour, taking out, cooling, and transferring into lOml volumetric flask, washing container with phosphate buffer solution (0.2moL/L, pH7.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is reference compound solution; accurately weighing 0.4g tablet of this invention pharmaceutical composition prepared in Example 2, placing it in lOmi test tube with plug, adding proper amount water, shaking up fully, heating up in 60°C water bath for 30 minutes, taking out, cooling, and transferring into lOmi volumetric flask, washing container with water by several times, combining the washing solution into volumetric flask and adding water to volume, and shaking up; centrifuging 12000 rpm for 10 minutes, measuring 2m1 the supernatant accurately, placing it into lOml test tube with plug, adding 2m1 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 2m1 sodium bicarbonate solution(0.5molIL), heating up in 60°Cwater bath for 1 hour, taking out, cooling, and transferring into lOmi volumetric flask, washing container with phosphate buffer solution (0.2moIlL, pH7.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is test sample solution, accurately sucking 0.005m1 reference substance solution and 0.Olml test sample solution respectively, injecting into liquid chromatogram instrument, determining, that is; dosage per day for the pharmaceutical composition of this inventionis 0.5g, then Feculae Bombycis content counted according to Pipecolic acid (C6H11NO2), is not less than 0.0018g.
EXAMPLE 12: PREPARATION OF TABLET Feculae Bombycis 7.15kg Radix Glycyrrhizae 0.1375kg Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recovering ethanol, concentrating at a temperature 55°C, gaining concentrated solution of the relative density of 1.01-1.06, adding same amount water and heating to boiling, cooling, placing overnight, then taking supematant A, heating the supernatant to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55 °C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 5 5°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process, adding general adjuvant, producing tablet.
EXAMPLE 13: PREPARATION OF GRANULE Feculae Bombycis 6.15kg Radix Glycyrrhizae 0.1875kg Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recovering ethanol, concentrating at a temperature 5 5°C, gaining concentrated solution of the relative density of 1.01-1.06, adding same amount water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating the supernatant to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55 °C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 5 5°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process, adding general adjuvant, producing granule.
EXAMPLE 14: PREPARATION OF PILL Feculae Bombycis 7.85kg Radix Glycyrrhizae 0.1175kg Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recovering ethanol, concentrating at a temperature 55°C, gaining concentrated solution of the relative density of 1.01-1.06, adding same amount water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating the supernatant to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55 °C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 5 5°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process, adding general adjuvant, producing pill.
EXAMPLE 15: PREPARATION OF HONEY REFINING PASTE Feculae Bombycis 7.15kg Radix Glycyrrhizae 0.1375kg Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recovering ethanol, concentrating at a temperature 5 5°C, gaining concentrated solution of the relative density of 1.01-1.06, adding same amount water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating the supernatant to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55 °C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 5 5°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process, adding general adjuvant, producing honey refining paste.
EXAMPLE 16: PREPARATION OF ORAL LIQUID PREPARATION Feculae Bombycis 6.15kg Radix Glycyrrhizae 0.1875kg Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recovering ethanol, concentrating at a temperature 55°C, gaining concentrated solution of the relative density of 1.01-1.06, adding same amount water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating the supernatant to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55 °C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 55°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process, adding general adjuvant, producing oral liquid preparation.
EXAMPLE 17: PREPARATION OF INJECTION Feculae Bombycis 7.85kg Radix Glycyrrhizae 0.1175kg Taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recovering ethanol, concentrating at a temperature 5 5°C, gaining concentrated solution of the relative density of 1.01-1.06, adding same amount water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating the supematant to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 5 5°C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 55°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process, adding general adjuvant, producing injection.
Claims (26)
- CLAIMS1. A pharmaceutical composition, wherein raw materials of this pharmaceutical composition consist of: Feculae Bombycis 6000-8000 parts by weight Radix Glycyrrhizae 100-200 parts by weight.
- 2. Said pharmaceutical composition of claim 1, wherein raw materials of this pharmaceutical composition consist of: Feculae Bombycis 7150 parts by weight Radix Glycyrrhizae 137.5 parts by weight.
- 3. Said pharmaceutical composition of claim 1, wherein raw materials of this pharmaceutical composition consist of: Feculae Bombycis 6150 parts by weight Radix Glycyrrhizae 187.5 parts by weight.
- 4. The said pharmaceutical composition of claim 1, wherein raw materials of this pharmaceutical composition consist of: Feculae Bombycis 7850 parts by weight Radix Glycyrrhizae 117.5 parts by weight.
- 5. Said pharmaceutical composition of claim 1, 2, 3 or 4, wherein this pharmaceutical composition is added general adjuvant, according to usual process, produced to tablet, capsule, powder, soft capsule, drop pill, honey pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection.
- 6. A preparation method of said pharmaceutical composition preparation of claim 1, 2, 3 or 4, wherein said method is: taking Feculae Bombycis, adding 5 0-70% ethanol at 2-6 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 1-3 times, each time 0.5-1.5 hours, filtering, combining the filtrates, recovering ethanol, after the ethanol is removed, heating the filtrates up to concentrate or vacuum concentrating the filtrates at a temperature below 80°C until the relative density of 0.95-1.10 (measured at the temperature 55 °C), then obtaining concentrated solution, adding water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating up to concentrate the supernatant, or vacuum concentrating the supernatant at 80°C to obtain the thick paste A with the relative density of 1.00-1.15 (measured at the temperature 55 °C), stand it by service; taking Radix Glycyrrhizae, adding 8-15 folds amount of Radix Glycyrrhizae with water, decocting 1-3 times, each time 1-3 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.00-1.15 (measured at a temperature 55°C), stand it by service; combining the thick paste A and the thick paste B, according to usual process by adding general adjuvant, then producing them to tablet, capsule, powder, soft capsule, drop pill, honey pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection.
- 7. Said preparation method of pharmaceutical composition preparation of claim 6, wherein this method is: taking Feculae Bombycis, adding 60% ethanol at 4 folds amount of Feculae Bombycis, soaking overnight, heating up slowly to boil, refluxing for 2 times, each time 1 hour, filtering, combining the filtrates, recovering ethanol, after the ethanol is removed, heating the filtrates up to concentrate or vacuum concentrating the filtrates at a temperature below 80°C until the relative density of 1.01-1.06 (measured at the temperature 55 °C), then obtaining concentrated solution, adding same amount water and heating to boiling, cooling, placing overnight, then taking supernatant A, heating up to concentrate the supernatant, or vacuum concentrated at 80°C to obtain the thick paste A with the relative density of 1.06-1.15 (measured at the temperature 55 °C), stand it by service; taking Radix Glycyrrhizae, adding 10 folds amount of Radix Glycyrrhizae with water, decocting 2 times, each time 2 hours, combining the decoctions, placing overnight to precipitate, concentrating the supernatant B to the thick paste B with the relative density of 1.04-1.15 (measured at a temperature 55 °C), stand it by service; combining the thick paste A and the thick paste B, according to usual process by adding general adjuvant, then producing them to tablet, capsule, powder, soft capsule, drop pill, honey pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection.
- 8. Quality control method of said pharmaceutical composition preparation of claim 1, 2, 3 or 4, wherein said method includes one or more of following identification andlor content determination: Identification: A. Taking 0.4-0.6 part by weight of this invention pharmaceutical composition, adding 4-6 parts by volume of anhydrous ethanol, refluxing in 40-80°C water bath for 20-40 minutes, placing and taking supernatant, evaporating it until 0.5-1.5 parts by volume above water bath, that is test sample solution; furthermore, taking 13-sitosterol as reference substance, adding anhydrous ethanol for 0.0005-0.0015 part by weight /volume solution, that is reference substance solution; according to thin layer chromatography test, sucking above two solutions 0.00 1-0.003 part by volume respectively, pointing them on the same TLC plate of silica gel G respectively, developing, taking out, drying, 18-21:0.3-0.7 of chloroform: acetone as mobile phase, and spraying with 5% -15% phosphor-molybdic acid solution, heating in 100-110°C until visualize the chromatogram; the chromatogram produced by the test sample solution shows the same color spots as that displayed by the reference substance solution in their respectively corresponding areas; B. Identification by high-performance liquid chromatography, using octadecylsilanized silica gel as packing; using methanol-(0.2mol / L) ammonium acetate -acetic acid = 50-70:30-50:0.5-1.5 as mobile phase; detection wavelength 250nm; theoretical plate number counted according to peak animonium glycyrrhizinate is not less than 2000; weighing 0.005-0.015 part by weight mono-ammonium glycyrrhizinate reference compound accurately, putting it into volumetric flask on 50 parts by volume, dissolving by above mobile phase to the volume, shaking up, that is, 0.0001-0.0003 part by weight of mono-ammonium glycyrrhizinate per part by volume, which is equivalent to 0.00019-0.00020 part by weight of glycyrrhizic acid, that is reference substance solution; taking 1.0-3.0 parts by weight of this invention pharmaceutical compositions, putting it into volumetric flask on 25 parts by volume, adding 18-22 parts by volume of above mobile phase, deal with ultrasound for 20-40 minutes with power 25 OW, frequency of 50KHz, taking out and cooling, adding mobile phase to the volume, shaking up, centrifuging, taking the supematant, that is test sample solution; Accurately sucking reference substance solution and test sample solution 0.005-0.015 part by volume respectively, injecting into liquid chromatogram instrument, test sample should be presented the same retention time peaks with the reference substance.Content determination: An applicability test of chromatogram condition and system Using octadecylsilanized silica gel as packing; using a solution with acetonitrile-dimethyl formamide-sodium acetate(0.025moL'L) 15-25: 0.1-1: 75-85 as mobile phase; detection wavelength is 390nm, theoretical plate number counted according to peak Pipecolic acid is not less than 2500; accurately weighing 0.004-0.006 part by weight of Pipecolic acid as reference compound, putting it into 50 parts by volume volumetric flask, adding water to dilute to the volume, shaking up, measuring 0.5-1.5 parts by volume the said solution accurately, putting it into test tube with plug of 10 parts by volume, adding 0.5-1.5 parts by volume water, adding 1-3 parts by volume 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 1-3 parts by volume sodium bicarbonate solution(0.5mol/L), heating up in 60°C water bath for 0.5-1.5 hours, taking out, cooling, and transferring into 10 parts by volume volumetric flask, washing container with phosphate buffer solution (0.2mol/L, pH7.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is reference compound solution; weighing 0.3-0.5 part by weight of this invention pharmaceutical composition accurately, placing it in test tube with plug of 10 parts by volume, adding water, shaking up fully, heating up in 5 0-70°C water bath for 20-40 minutes, taking out, cooling, and transferring into volumetric flask of 10 parts by volume, washing container with water by several times, combining the washing solution into volumetric flask and adding water to volume, and shaking up; centrifuging 12000 rpm for 5-15 minutes, measuring 1-3 parts by volume the supernatant accurately, placing it into 10 parts by volume test tube with plug, adding 1-3 parts by volume 2,4-acetonitrile dinitrofluorobenzene solution(0.8%) and 1-3 parts by volume sodium bicarbonate solution(0.5mol/L), heating up in 50-70°C water bath for 0.5-1.5 hours, taking out, cooling, and transferring into 10 parts by volume volumetric flask, washing container with phosphate buffer solution (0.2mol/L, pH7.0) by several times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is test sample solution, Accurately sucking 0.004-0.006 part by volume of reference substance solution and 0.005-0.0 15 part by volume of test sample solution respectively, injecting into liquid chromatogram instrument, determining, that is; Feculae Bombycis content in dosage per day of this invention pharmaceutical composition, counted according to Pipecolic acid (C6H11N02), is not less than 0.0001-0.0003 part by weight.
- 9. Said quality control method of pharmaceutical composition preparation of claim 8, wherein said method includes one or more of following identification and/or content determination: Identification: A. Taking 0.5 part by weight of this invention pharmaceutical composition, adding parts by volume of anhydrous ethanol, refluxing in 60°C water bath for 30 minutes, placing and taking supematant, evaporating it until 1 part by volume above water bath, that is test sample solution; furthermore, taking 3-sitosterol as reference substance, adding anhydrous ethanol for 0.001 part by weight /volume solution, that is reference substance solution; according to thin layer chromatography test, sucking above two solutions 0.002 part by volume respectively, pointing them on the same TLC plate of silica gel G respectively, developing, taking out, drying, 19.5:0.5 of chloroform: acetone as mobile phase, and spraying with 10% phosphor-molybdic acid solution, heating in 105°C until visualize the chromatogram; the chromatogram produced by the test sample solution shows the same color spots as that displayed by the reference substance solution in their respectively corresponding areas; B. Identification by high-performance liquid chromatography, Using octadecylsilanized silica gel as packing; using methanol-(0.2mol / L) ammonium acetate -acetic acid = 60:40:1 as mobile phase; detection wavelength 250nm; theoretical plate number counted according to peak ammonium glycyrrhizinate is not less than 2000; weighing 0.01 part by weight of mono-ammonium glycyrrhizinate reference compound accurately, putting it into volumetric flask on 50 parts by volume, dissolving by above mobile phase to the volume, shaking up, that is, 0.0002 part by weight of mono-ammonium glycyrrhizinate per part by volume, which is equivalent to 0.0001959 part by weight of glycyrrhizic acid, that is reference substance solution; taking 2 parts by weight of this invention pharmaceutical compositions, putting it into volumetric flask on 25 parts by volume, adding 20 parts by volume of above mobile phase, deal with ultrasound for 30 minutes with power 250W, frequency of 50KHz, taking out and cooling, adding mobile phase to the volume, shaking up, centrifuging, taking the supernatant, that is test sample solution; accurately sucking reference substance solution and test sample solution 0.01 part by volume respectively, injecting into liquid chromatogram instrument, test sample should be presented the same retention time peaks with the reference substance.Content determination: An applicability test of chromatogram condition and system Using octadecylsilanized silica gel as packing; using a solution with acetonitrile-dimethyl formamide-sodium acetate(0.O2Smol/L) 21:0.5:79 as mobile phase; detection wavelength is 390nm, theoretical plate number counted according to peak Pipecolic acid is not less than 2500; accurately weighing 0.01 part by weight of Pipecolic acid as reference compound, putting it into volumetric flask of 100 parts by volume, adding water to dilute to the volume, shaking up, measuring 1 part by volume of the said solution accurately, putting it into test tube with plug of 10 parts by volume, adding 1 part by volume of water, adding 2 parts by volume of 2,4-acetonitrile dinitrofluorobenzene solution(O.8%) and 2 parts by volume of sodium bicarbonate solution(0.Smol/L), heating up in 60°C water bath for 1 hour, taking out, cooling, and transferring into volumetric flask of 10 parts by volume, washing container with phosphate buffer solution (0.2molIL, pH7.0) by 3 times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is reference compound solution; weighing 0.4 part by weight of this invention pharmaceutical composition accurately, placing it in test tube with plug of 10 parts by volume, adding 5 parts by volume of water, shaking up fully, heating up in 60°C water bath for 30 minutes, taking out, cooling, and transferring into volumetric flask of 10 parts by volume, washing container with water by 3 times, combining the washing solution into volumetric flask and adding water to volume, and shaking up; centrifuging 12000 rpm for 10 minutes, measuring 2 parts by volume of the supernatant accurately, placing it into test tube with plug of 10 parts by volume, adding 2 parts by volume of 2,4-acetonitrile dinitrofluorobenzene solution(O.8%) and 2 parts by volume of sodium bicarbonate solution(0.5mol/L), heating up in 60°C water bath for 1 hour, taking out, cooling, and transferring into volumetric flask of 10 parts by volume, washing container with phosphate buffer solution (0.2mol/L, pH7.0) by 3 times, combining the washing solution into volumetric flask, adding phosphate buffer solution to the volume, shaking up, that is test sample solution, accurately sucking 0.005 part by volume reference substance solution and 0.01 part by volume test sample solution respectively, injecting into liquid chromatogram instrument, determining, that is; Feculae Bombycis content in dosage per day of this invention pharmaceutical composition, counted according to Pipecolic acid (C6H1 1N02), is not less than 0.0002 part by weight.
- 10. Use of said pharmaceutical composition of claim 1, 2, 3 or 4 in the preparation of a medicine for treating diabetes.
- 11. The use of claim 10, wherein said treating diabetes is to improve on the symptoms of polydipsia or polyphagia.
- 12. The use of claim 10, wherein said treating diabetes is to decrease blood glucose and serum fructosamine significantly.
- 13. The use of claim 10, wherein said treating diabetes is to decrease serum cholesterol and triglyceride levels.
- 14. The use of claim 10, wherein said treating diabetes is to decrease serum NAG-ase activity and improve microvascular complications.
- 15. The use of claim 10, wherein said treating diabetes is to decrease sorbitol content in sciatic nerve and improve chronic neuropathy of diabetes.
- 16. The use of claim 10, wherein said treating diabetes is to increase GSH content in red blood cell, and enhance body's antioxidant capacity.
- 17. The use of claim 10, wherein said treating diabetes is to lower kidney weight and body mass index, reduce serum creatinine levels, relief glycogen deposition in renal tubular epithelial cells.
- 18. Use of said pharmaceutical composition of claim 1, 2, 3 or 4 in treating diabetes.
- 19. The use of claim 18, wherein said treating diabetes is to improve on the symptoms of polydipsia or polyphagia.
- 20. The use of claim 18, wherein said treating diabetes is to decrease blood glucose and serum fructosamine significantly.
- 21. The use of claim 18, wherein said treating diabetes is to decrease serum cholesterol and triglyceride levels.
- 22. The use of claim 18, wherein said treating diabetes is to decrease serum NAG-ase activity and improve microvascular complications.
- 23. The use of claim 18, wherein said treating diabetes is to decrease sorbitol content in sciatic nerve and improve chronic neuropathy of diabetes.
- 24. The use of claim 18, wherein said treating diabetes is to increase GSH content in red blood cell, and enhance body's antioxidant capacity.
- 25. The use of claim 18, wherein said treating diabetes is to lower kidney weight and body mass index, reduce serum creatinine levels, relief glycogen deposition in renal tubular epithelial cells.
- 26. The use of claim 18, wherein said treating diabetes is to inhibit a-glucosidase activity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100571303A CN101496829B (en) | 2008-01-30 | 2008-01-30 | Medicament composition for treating diabetes and preparation method thereof |
| PCT/CN2008/001878 WO2009100605A1 (en) | 2008-01-30 | 2008-11-14 | A pharmaceutical composition for treating diabetes and preparation methods thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB201009713D0 GB201009713D0 (en) | 2010-07-21 |
| GB2469220A true GB2469220A (en) | 2010-10-06 |
| GB2469220B GB2469220B (en) | 2012-10-24 |
Family
ID=40944238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1009713.7A Active GB2469220B (en) | 2008-01-30 | 2008-11-14 | Pharmaceutical composition for treating diabetes and preparation method thereof |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN101496829B (en) |
| CA (1) | CA2710862C (en) |
| GB (1) | GB2469220B (en) |
| WO (1) | WO2009100605A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104095178A (en) * | 2013-04-09 | 2014-10-15 | 北京宏泰康达医药科技有限公司 | Composition used for assistant reduction of blood sugar |
| CN103536649B (en) * | 2013-10-17 | 2015-05-20 | 漳州片仔癀药业股份有限公司 | Preparation method of Jintangning capsules |
| CN104007205B (en) * | 2014-06-13 | 2015-09-30 | 漳州片仔癀药业股份有限公司 | A kind of detection method for the treatment of the pharmaceutical preparation of diabete |
| CN104007206B (en) * | 2014-06-13 | 2015-05-27 | 漳州片仔癀药业股份有限公司 | Method for detecting silkworm excrement medicinal materials |
| CN105004829B (en) * | 2015-07-21 | 2017-06-16 | 漳州片仔癀药业股份有限公司 | A kind of quality determining method of Jintangning capsule |
| CN109007145A (en) * | 2018-07-26 | 2018-12-18 | 佛山科学技术学院 | A kind of preparation method of multiple-effect health-care black tea beverage |
| CN110279719B (en) * | 2019-06-27 | 2021-01-15 | 北京市房山区中医医院 | Night silkworm excrement external ironing bag for treating diabetic gastroparesis and preparation and use methods thereof |
| CN114594178B (en) * | 2022-01-25 | 2024-04-02 | 贵州健安德科技有限公司 | Method for detecting 3-methylpyridine in 30% chlorantraniliprole suspending agent by utilizing HPLC |
| CN117298154A (en) * | 2023-10-11 | 2023-12-29 | 北京市房山区中医医院 | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277027A (en) * | 1999-06-14 | 2000-12-20 | 中国医学科学院药物研究所 | Silkworm excrement extracting process, extract and its use |
| KR20030079237A (en) * | 2002-04-02 | 2003-10-10 | 최진호 | Composition of anti-diabetes patient food using silkworm extract |
| CN1557824A (en) * | 2004-02-13 | 2004-12-29 | 南开大学 | Total alkaloids of silkworm excrement and preparation method thereof |
| CN1559539A (en) * | 2004-02-23 | 2005-01-05 | 南开大学 | Pharmaceutical composition having alpha-glucosidase inhibitory activity and use thereof |
| CN1817350A (en) * | 2005-12-09 | 2006-08-16 | 南开大学 | Silkworm sand total alkaloid and preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908628A (en) * | 1998-05-01 | 1999-06-01 | Hou; Liping | Compositions with analgesic, antipyretic and antiinflammatory properties |
| US6350476B1 (en) * | 2000-05-22 | 2002-02-26 | Shanxi Zhengzhon Pharmaceutical Co., Ltd. | Herbal chinese joint complex |
| US20070160687A1 (en) * | 2004-02-06 | 2007-07-12 | Kim Jin S | Composition for prevention and treatment of diabetic complication |
| CN100425268C (en) * | 2005-11-15 | 2008-10-15 | 李乃荣 | Medicament for treating gout |
-
2008
- 2008-01-30 CN CN2008100571303A patent/CN101496829B/en active Active
- 2008-11-14 CA CA2710862A patent/CA2710862C/en active Active
- 2008-11-14 GB GB1009713.7A patent/GB2469220B/en active Active
- 2008-11-14 WO PCT/CN2008/001878 patent/WO2009100605A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277027A (en) * | 1999-06-14 | 2000-12-20 | 中国医学科学院药物研究所 | Silkworm excrement extracting process, extract and its use |
| KR20030079237A (en) * | 2002-04-02 | 2003-10-10 | 최진호 | Composition of anti-diabetes patient food using silkworm extract |
| CN1557824A (en) * | 2004-02-13 | 2004-12-29 | 南开大学 | Total alkaloids of silkworm excrement and preparation method thereof |
| CN1559539A (en) * | 2004-02-23 | 2005-01-05 | 南开大学 | Pharmaceutical composition having alpha-glucosidase inhibitory activity and use thereof |
| CN1817350A (en) * | 2005-12-09 | 2006-08-16 | 南开大学 | Silkworm sand total alkaloid and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| China Pharmaceuticals, Vol. 83, no. 16, 2007, Xiaoying Wang et al., "Effects of glycyrrhiza on rats with diabetes mellitus induced by D-galactose", pages 8-10. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009100605A1 (en) | 2009-08-20 |
| CA2710862A1 (en) | 2009-08-20 |
| CA2710862C (en) | 2019-02-26 |
| CN101496829A (en) | 2009-08-05 |
| CN101496829B (en) | 2011-09-14 |
| GB201009713D0 (en) | 2010-07-21 |
| GB2469220B (en) | 2012-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2710862C (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| Du et al. | Data mining-guided alleviation of hyperuricemia by Paeonia veitchii Lynch through inhibition of xanthine oxidase and regulation of renal urate transporters | |
| Sharma et al. | Cichorium intybus attenuates streptozotocin induced diabetic cardiomyopathy via inhibition of oxidative stress and inflammatory response in rats | |
| Deng et al. | Anti-hyperglycemic effects and mechanism of traditional Chinese medicine Huanglian Wan in streptozocin-induced diabetic rats | |
| CN103536635A (en) | Preparation method of holothuria nobilis and application thereof in treatment of diabetes mellitus | |
| CN101810625A (en) | Application of dandelion sterols | |
| CN110787230B (en) | Traditional Chinese medicine extract composition for treating diabetes and diabetic nephropathy and quality detection method | |
| CN103599117B (en) | Use of szechuan melandium root pentacyclic triterpenoid saponin compound in preparation of drug for reducing blood sugar | |
| CN101336964A (en) | A kind of mulberry bark extract with hypoglycemic activity and preparation method thereof | |
| CN101406542A (en) | Chinese medicine oral preparation for relieving cough, relieving asthma and dispelling phlegm | |
| CN101554406B (en) | Extraction process and formulation of mulberry cortex hypoglycemic medicinal active material | |
| CN102068475A (en) | Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part | |
| CN105920051A (en) | Needle mushroom extract and preparation method and application thereof | |
| KR100473530B1 (en) | Composition containing an extract of sopungsungi-won crude drug complex for preventing and treating diabetes mellitus | |
| CN113397016B (en) | Preparation method of dogwood and hawthorn table tea for reducing blood sugar | |
| CN103191222B (en) | Application of hedan preparation in preparation of diabetes medicine | |
| CN102153630A (en) | Ring octapeptide and preparation method and application thereof in medicament making | |
| CN100400091C (en) | Chinese patent medicine capsule for treating biliary tract disease | |
| CN106608899B (en) | The preparation method and medical usage of 20 (R)-protopanaxatriols and derivative | |
| CN109646446A (en) | Oleanolic acid type saponin class compound is preparing the application in Weight-lossing hypolipemic medicine | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| Liu et al. | MODULATION OF INSULIN RESISTANCE BY DIHYDROMYRICETIN IN T2DM RATS. | |
| CN101491581A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| KR20030059952A (en) | Composition containing an extract of truncated sopungsungi-won crude drug complex for preventing and treating diabetes | |
| Lin et al. | Antidiabetic Properties and Possible Mechanism of the Traditional Chinese Medicine Yi Qi Yang Yin Recipe in Db/db Mice |